Canada NewsWire TORONTO, Dec. 9, 2024 Costs for people with cancer and caregivers are expected to be a staggering $7.5 billion in 2024, placing an immense financial burden on people who are already facing a life-threatening illness. ...
PR Newswire LUND, Sweden, Dec. 9, 2024 LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of ...
PR Newswire BUFFALO, N.Y., Dec. 8, 2024 Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the ...
PR Newswire SAN DIEGO, Dec. 8, 2024 New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years Subgroup analysis from Phase 3 ...
PR Newswire SUZHOU, China, Dec. 8, 2024 SUZHOU, China, Dec. 8, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer ...
PR Newswire SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures ...
PR Newswire NORTH CHICAGO, Ill., Dec. 8, 2024 -New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys-CLL is ...
PR Newswire SAN DIEGO, Dec. 8, 2024 100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO, Dec. 8, 2024 ...
PR Newswire BUFFALO, N.Y., Dec. 8, 2024 The results of two important lymphoma studies led by experts at Roswell Park will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of ...
PR Newswire SAN DIEGO, Dec. 8, 2024 First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study ...
Discover how a gut-on-chip device predicts melanoma patients' response to immunotherapy by simulating intestinal inflammation and microbiota interaction.
New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.
Vitamin E succinate has been found to inhibit tumor growth and enhance the effectiveness of immunotherapy by targeting critical elements of tumor development.
Discover how a simple saliva test offers a painless and reliable method for early oral cancer detection, potentially replacing invasive biopsies.
Discover why cancer cases have doubled in India since 1990. Learn about causes, prevention, and advancements in treatment.
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers